Cresco Labs has completed the expansion project for its cultivation and manufacturing facility located in Brookville, Pa. "The expansion project provides an additional 66,000 square feet of indoor and greenhouse cultivation area, bringing the total cultivation space in the facility to 88,000 square feet," the team with the company explains. "The Brookville site supplies Cresco’s house of brands to 100% of the licensed dispensaries in Pennsylvania and the company currently maintains one of the largest wholesale market shares."
"The company also concluded a significant expansion of its manufacturing capabilities with new and advanced extraction booths and integrated safety systems. The expansion project provides a 300% increase in capacity for butane extraction and a 90% increase in ethanol extraction which enables Cresco to efficiently process its increased biomass to manufacture its full portfolio of brands, including Cresco, Remedi and Reserve, with new brands launching soon. As a result of tripling the site’s capacity in a phased approach, the company expects products from the third, 22,000-square-foot phase to enter the market this month, with production from the fourth, 22,000-square-foot phase starting in July 2020 and gradually increasing throughout the remainder of the year."
Charlie Bachtell, Cresco Labs’ CEO and co-founder, said, “Pennsylvania continues to be one of the most attractive and highly coveted markets in the country. Today’s announcement marks a strategic milestone towards building our leadership in this high-growth market. This expansion enables us to more efficiently cater to patients across the Keystone State and increase our operating leverage. This expansion project follows the recently completed scale up of our cultivation facilities in Lincoln and Kankakee, Ill. It is testament to our stated strategy of going deep in key states and focusing on branded products and wholesale distribution.”
Pennsylvania is a high-barrier, limited license market that is expected to become one of the biggest medical markets in the U.S. and has already witnessed rapid demand acceleration with over 284,000 registered patients and nearly 80 operational dispensaries as of April 2020.
For more information:
Cresco Labs
520 W Erie St Suite #220
Chicago, IL 60654
312-929-0993
[email protected]
crescolabs.com